Personal information

No personal information available

Activities

Collapse all

Employment (3)

Hunan University: Changsha, CN

2021-09 to present | Assistant Professor (College of Biology)
Employment
Source: Self-asserted source
Chun-Hui Zhang

Yale University: New Haven, US

2019-09 to 2021-07 | Postdoc (Department of Chemistry)
Employment
Source: Self-asserted source
Chun-Hui Zhang

University of Kentucky: Lexington, KY, US

2016-07 to 2019-07 | Postdoc (Department of Pharmaceutical Sciences)
Employment
Source: Self-asserted source
Chun-Hui Zhang

Education and qualifications (2)

Sichuan University: Chengdu, Sichuan, CN

2011-09 to 2016-06 | PhD (State Key Laboratory of Biotherapy and Cancer Center)
Education
Source: Self-asserted source
Chun-Hui Zhang

Sichuan University: Chengdu, Sichuan, CN

2007-09 to 2011-06 | BS (College of Chemical Engineering)
Education
Source: Self-asserted source
Chun-Hui Zhang

Works (16)

The FERONIA-RESPONSIVE TO DESICCATION 26 module regulates vascular immunity to Ralstonia solanacearum

The Plant Cell
2024-12-23 | Journal article
DOI: 10.1093/plcell/koae302
Contributors: Bingqian Wang; Cailin Luo; Xiaoxu Li; Alvaro Jimenez; Jun Cai; Jia Chen; Changsheng Li; Chunhui Zhang; Lijun Ou; Wenxuan Pu et al.
Source: check_circle
Crossref

Proof-of-concept studies with a computationally designed M pro inhibitor as a synergistic combination regimen alternative to Paxlovid

Proceedings of the National Academy of Sciences
2024-04-23 | Journal article
DOI: 10.1073/pnas.2320713121
Contributors: Christina Papini; Irfan Ullah; Amalendu P. Ranjan; Shuo Zhang; Qihao Wu; Krasimir A. Spasov; Chunhui Zhang; Walther Mothes; Jason M. Crawford; Brett D. Lindenbach et al.
Source: check_circle
Crossref

Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease

Structure
2021-08 | Journal article
DOI: 10.1016/j.str.2021.06.002
Contributors: Maya G. Deshmukh; Joseph A. Ippolito; Chun-Hui Zhang; Elizabeth A. Stone; Raquel A. Reilly; Scott J. Miller; William L. Jorgensen; Karen S. Anderson
Source: check_circle
Crossref

Progress of small molecular inhibitors in the development of anti-influenza virus agents

Theranostics
2017 | Journal article
DOI: 10.7150/thno.17071
Source: Self-asserted source
Chun-Hui Zhang
grade
Preferred source (of 2)‎

Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure–activity relationship analysis

Bioorganic & Medicinal Chemistry Letters
2016 | Journal article
DOI: http://dx.doi.org/10.1016/j.bmcl.2016.03.048
Source: Self-asserted source
Chun-Hui Zhang

From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer

Journal of Medicinal Chemistry
2016 | Journal article
DOI: 10.1021/acs.jmedchem.6b00943
Source: Self-asserted source
Chun-Hui Zhang
grade
Preferred source (of 2)‎

Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer

Mol Cancer Ther
2016 | Journal article
DOI: 10.1158/1535-7163.MCT-15-0501
Source: Self-asserted source
Chun-Hui Zhang

Design, synthesis, and structure-activity relationship studies of 3-(phenylethynyl)-1H-pyrazolo 3,4-d pyrimidin-4-amine derivatives as a new class of Src inhibitors with potent activities in models of triple negative breast cancer

Journal of Medicinal Chemistry
2015 | Journal article
DOI: 10.1021/acs.jmedchem.5b00270
Source: Self-asserted source
Chun-Hui Zhang

Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors

Bioorg Med Chem Lett
2015 | Journal article
DOI: 10.1016/j.bmcl.2015.08.068
Source: Self-asserted source
Chun-Hui Zhang
grade
Preferred source (of 2)‎

Structural modification of an EGFR inhibitor that showed weak off-target activity against RET leading to the discovery of a potent RET inhibitor

Molecular Diversity
2014 | Journal article
DOI: 10.1007/s11030-014-9508-8
Source: Self-asserted source
Chun-Hui Zhang

Retrieving novel C5aR antagonists using a hybrid ligand-based virtual screening protocol based on SVM classification and pharmacophore models

Journal of Biomolecular Structure & Dynamics
2013 | Journal article
DOI: 10.1080/07391102.2012.698245
Source: Self-asserted source
Chun-Hui Zhang

Discovery of the Novel Potent and Selective FLT3 Inhibitor 1-5- 7-(3-Morpholinopropoxy)quinazolin-4-ylthio - 1,3,4 thiadiazol-2-yl -3-p-tolylurea and Its Anti-Acute Myeloid Leukemia (AML) Activities in Vitro and in Vivo

Journal of Medicinal Chemistry
2012 | Journal article
DOI: 10.1021/jm300042x
Source: Self-asserted source
Chun-Hui Zhang

Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking

Journal of molecular graphics & modelling
2012 | Journal article
DOI: 10.1016/j.jmgm.2012.03.004
Source: Self-asserted source
Chun-Hui Zhang

SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants

Leukemia
2012 | Journal article
DOI: 10.1038/leu.2012.67
Source: Self-asserted source
Chun-Hui Zhang
grade
Preferred source (of 2)‎

Structural Optimization and Structure-Activity Relationships of N-2-(4-(4-Methylpiperazin-1-yl)phenyl)-N-8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations

Journal of Medicinal Chemistry
2012 | Journal article
DOI: 10.1021/jm301365e
Source: Self-asserted source
Chun-Hui Zhang

Discovery and Structure-Activity Analysis of 4-((5-nitropyrimidin-4-yl) amino) benzimidamide Derivatives as Novel Protein Arginine Methyltransferase 1 (PRMT1) Inhibitors

Bioorganic & Medicinal Chemistry Letters
Journal article
DOI: http://dx.doi.org/10.1016/j.bmcl.2015.06.095
Source: Self-asserted source
Chun-Hui Zhang
grade
Preferred source (of 2)‎

Peer review (10 reviews for 6 publications/grants)

Review activity for ACS omega. (2)
Review activity for Chemistry & biodiversity. (1)
Review activity for ChemistrySelect (1)
Review activity for ChemMedChem. (1)
Review activity for Molecular diversity. (4)
Review activity for Signal transduction and targeted therapy. (1)
How many people are using ORCID?